The preoperative diagnosis of borderline ovarian tumors: A review of current literature

Archives of Gynecology and Obstetrics

Volumn 285, Issue 4, 2012, Pages 1103-1112

  Morotti, Matteo ^a   Menada, Mario Valenzano ^a   Gillott, David John ^b   Venturini, Pier Luigi ^a   Ferrero, Simone ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Borderline ovarian tumors; Magnetic resonance imaging; Preoperative; Serum tumor markers; Sonography

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CALGRANULIN; CARCINOEMBRYONIC ANTIGEN; CONTRAST MEDIUM; ENDOGLIN; FLUORODEOXYGLUCOSE F 18; GLYCOPROTEIN; GROWTH DIFFERENTIATION FACTOR 15; OVIDUCTAL GLYCOPROTEIN 1; SHU 508; SIALYL STAGE SPECIFIC EMBRYO ANTIGEN 1; SONOVUE; TETRANECTIN; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

BORDERLINE OVARY TUMOR; CANCER STAGING; CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; GYNECOLOGIC SURGERY; HISTOPATHOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; OVARY TUMOR; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; SYMPTOM; SYSTEMATIC REVIEW; TRANSVAGINAL ECHOGRAPHY; TUMOR VASCULARIZATION; BLOOD; FEMALE; NEOPLASM; PATHOLOGY; PREOPERATIVE CARE;

FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PREOPERATIVE CARE; TUMOR MARKERS, BIOLOGICAL;

EID: 84863217299     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-011-2194-1     Document Type: Review

References (76)

1. Chu CS, Rubin SC (2006) Epidemiology, staging and clinical characteristics. In: Bristow RE, Karlan BY (eds) Surgery for ovarian cancer: principles and practice, 1st edn. Taylor & Francis, Abington, pp 1-37
2. Swanton A, Bankhead CR, Kehoe S (2007) Pregnancy rates after conservative treatment for borderline ovarian tumours: a systematic review. Eur J Obstet Gynecol Reprod Biol 135:3-7
3. Wong HF, Low JJ, Chua Y et al (2007) Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004. Int J Gynecol Cancer 17:342-349
4. Goff BA, Mandel LS, Melancon CH et al (2004) Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 291:2705-2712
5. Hamilton W, Peters TJ, Bankhead C et al (2009) Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. BMJ 339:b2998
6. Ranney B, Ahmad MI (1979) Early identification, differentiation and treatment of ovarian neoplasia. Int J Gynaecol Obstet 17:209-218
7. Eltabbakh GH, Yadav PR, Morgan A (1999) Clinical picture of women with early stage ovarian cancer. Gynecol Oncol 75:476-479
8. Vine MF, Ness RB, Calingaert B et al (2001) Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor. Gynecol Oncol 83:466-471
9. Webb PM, Purdie DM, Grover S et al (2004) Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer. Gynecol Oncol 92:232-239
10. Olsen CM, Cnossen J, Green AC et al (2007) Comparison of symptoms and presentation of women with benign, low malignant potential and invasive ovarian tumors. Eur J Gynaecol Oncol 28:376-380
11. Paulsen T, Kaern J, Kjaerheim K et al (2005) Symptoms and referral of women with epithelial ovarian tumors. Int J Gynaecol Obstet 88:31-37
12. Rice LW, Lage JM, Berkowitz RS et al (1992) Preoperative serum CA-125 levels in borderline tumors of the ovary. Gynecol Oncol 46:226-229
13. Zanetta G, Vergani P, Lissoni A (1994) Color Doppler ultrasound in the preoperative assessment of adnexal masses. Acta Obstet Gynecol Scand 73:637-641
14. Darai E, Teboul J, Walker F et al (1996) Epithelial ovarian carcinoma of low malignant potential. Eur J Obstet Gynecol Reprod Biol 66:141-145
15. Tamakoshi K, Kikkawa F, Shibata K et al (1996) Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. Gynecol Oncol 62:67-72
16. Engelen MJ, de Bruijn HW, Hollema H et al (2000) Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors. Gynecol Oncol 78:16-20
17. Gotlieb WH, Soriano D, Achiron R et al (2000) CA 125 measurement and ultrasonography in borderline tumors of the ovary. Am J Obstet Gynecol 183:541-546
18. Takemori M, Nishimura R, Hasegawa K (2002) Clinical evaluation of MRI in the diagnosis of borderline ovarian tumors. Acta Obstet Gynecol Scand 81:157-161
19. Ayhan A, Guven S, Guven ES et al (2007) Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? Acta Obstet Gynecol Scand 86:484-490
20. Kumpulainen S, Kuoppala T, Leminen A et al (2007) Surgical staging, treatment, and follow-up of borderline tumors in different hospital categories: a prospective nationwide survey in Finland. Acta Obstet Gynecol Scand 86:610-614
21. Kolwijck E, Thomas CM, Bulten J et al (2009) Preoperative CA-125 levels in 123 patients with borderline ovarian tumors: a retrospective analysis and review of the literature. Int J Gynecol Cancer 19:1335-1338
22. Lenhard MS, Nehring S, Nagel D et al (2009) Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors. Clin Chem Lab Med 47:537-542
23. Van Calster B, Timmerman D, Bourne T et al (2007) Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. J Natl Cancer Inst 99:1706-1714
24. Tempfer CB, Polterauer S, Bentz EK et al (2007) Accuracy of intraoperative frozen section analysis in borderline tumors of the ovary: a retrospective analysis of 96 cases and review of the literature. Gynecol Oncol 107:248-252
25. Kelly PJ, Archbold P, Price JH et al (2010) Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. J Clin Pathol 63:169-173
26. Hata K, Hata T, Manabe A et al (1992) Ovarian tumors of low malignant potential: transvaginal Doppler ultrasound features. Gynecol Oncol 45:259-264
27. Ehrchen JM, Sunderkötter C, Foell D et al (2009) The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 86:557-566
28. Ferrero S, Gillott DJ, Remorgida V et al (2007) Proteomic analysis of peritoneal fluid in women with endometriosis. J Proteome Res 6:3402-3411
29. Ødegaard E, Davidson B, Elgaaen BV et al (2008) Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary. Am J Obstet Gynecol 198:418.e1-7
30. Ødegaard E, Davidson B, Engh V et al (2008) Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary. Am J Obstet Gynecol 199:533.e1-8
31. Maines-Bandiera S, Woo MM, Borugian M et al (2010) Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer. Int J Gynecol Cancer 20:16-22
32. Staff AC, Bock AJ, Becker C et al (2010) Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol Oncol 118:237-243
33. Begum FD, Høgdall E, Kjaer SK et al (2009) Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors. Gynecol Oncol 113:221-227
34. Pascual MA, Tresserra F, Grases PJ et al (2002) Borderline cystic tumors of the ovary: gray-scale and color Doppler sonographic findings. J Clin Ultrasound 30:76-82
35. Exacoustos C, Romanini ME, Rinaldo D et al (2005) Preoperative sonographic features of borderline ovarian tumors. Ultrasound Obstet Gynecol 25:50-59
36. Fruscella E, Testa AC, Ferrandina G et al (2005) Ultrasound features of different histopathological subtypes of borderline ovarian tumors. Ultrasound Obstet Gynecol 26:644-650
37. Yazbek J, Raju KS, Ben-Nagi J et al (2007) Accuracy of ultrasound subjective 'pattern recognition' for the diagnosis of borderline ovarian tumors. Ultrasound Obstet Gynecol 29:489-495
38. Alcázar JL, Errasti T, M?́nguez JA et al (2001) Sonographic features of ovarian cystadenofibromas: spectrum of findings. J Ultrasound Med 20:915-919
39. Emoto M, Udo T, Obama H et al (1998) The blood flow characteristics in borderline ovarian tumors based on both color Doppler ultrasound and histopathological analyses. Gynecol Oncol 70:351-357
40. Wu CC, Lee CN, Chen TM et al (1994) Incremental angiogenesis assessed by color Doppler ultrasound in the tumorigenesis of ovarian neoplasms. Cancer 73:1251-1256
41. Tepper R, Lerner-Geva L, Altaras MM et al (1995) Transvaginal color flow imaging in the diagnosis of ovarian tumors. J Ultrasound Med 14:731-734
42. Reles A, Wein U, Lichtenegger W (1997) Transvaginal color Doppler sonography and conventional sonography in the preoperative assessment of adnexal masses. J Clin Ultrasound 25:217-225
43. Tekay A, Jouppila P (1992) Validity of pulsatility and resistance indices in classification of adnexal tumors with transvaginal color Doppler ultrasound. Ultrasound Obstet Gynecol 2:338-344
44. Zanetta G, Lissoni A, Cha S et al (1995) Pre-operative morphological and colour Doppler features of borderline ovarian tumours. Br J Obstet Gynaecol 102:990-996
45. Yazbek J, Ameye L, Timmerman D et al (2010) Use of ultrasound pattern recognition by expert operators to identify borderline ovarian tumors: a study of diagnostic performance and interobserver agreement. Ultrasound Obstet Gynecol 35:84-88
46. Ordén MR, Jurvelin JS, Kirkinen PP (2003) Kinetics of a US contrast agent in benign and malignant adnexal tumors. Radiology 226:405-410
47. Marret H, Sauget S, Giraudeau B et al (2004) Contrast-enhanced sonography helps in discrimination of benign from malignant adnexal masses. J Ultrasound Med 23:1629-1639
48. Testa AC, Timmerman D, Van Belle V et al (2009) Intravenous contrast ultrasound examination using contrast-tuned imaging (CnTI) and the contrast medium SonoVue for discrimination between benign and malignant adnexal masses with solid components. Ultrasound Obstet Gynecol 34:699-710
49. Lalwani N, Shanbhogue AK, Vikram R et al (2010) Current update on borderline ovarian neoplasms. AJR Am J Roentgenol 194:330-336
50. Bent CL, Sahdev A, Rockall AG et al (2009) MRI appearances of borderline ovarian tumours. Clin Radiol 64:430-438
51. deSouza NM, O'Neill R, McIndoe GA et al (2005) Borderline tumors of the ovary: CT and MRI features and tumor markers in differentiation from stage I disease. AJR Am J Roentgenol 184:999-1003
52. Bazot M, Dara?̈ E, Nassar-Slaba J et al (2008) Value of magnetic resonance imaging for the diagnosis of ovarian tumors: a review. J Comput Assist Tomogr 32:712-723
53. Van Vierzen PB, Massuger LF, Ruys SH et al (1998) Borderline ovarian malignancy: ultrasound and fast dynamic MR findings. Eur J Radiol 28:136-142
54. Imaoka I, Wada A, Kaji Y et al (2006) Developing an MR imaging strategy for diagnosis of ovarian masses. Radiographics 26:1431-1448
55. Thomassin-Naggara I, Bazot M, Dara?̈ E et al (2008) Epithelial ovarian tumors: value of dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis. Radiology 248:148-159
56. Thomassin-Naggara I, Cuenod CA, Darai E et al (2008) Dynamic contrast-enhanced MR imaging of ovarian neoplasms: current status and future perspectives. Magn Reson Imaging Clin N Am 16:661-672
57. Bazot M, Nassar-Slaba J, Thomassin-Naggara I et al (2006) MR imaging compared with intraoperative frozen-section examination for the diagnosis of adnexal tumors; correlation with final histology. Eur Radiol 16:2687-2699
58. Spencer JA, Ghattamaneni S (2010) MR imaging of the sonographically indeterminate adnexal mass. Radiology 256:677-694
59. Fujii S, Kakite S, Nishihara K et al (2008) Diagnostic accuracy of diffusion-weighted imaging in differentiating benign from malignant ovarian lesions. J Magn Reson Imaging 28:1149-1156
60. Thomassin-Naggara I, Dara?̈ E, Cuenod CA et al (2009) Contribution of diffusion-weighted MR imaging for predicting benignity of complex adnexal masses. Eur Radiol 19:1544-1552
61. Takeuchi M, Matsuzaki K, Nishitani H (2010) Diffusion-weighted magnetic resonance imaging of ovarian tumors: differentiation of benign and malignant solid components of ovarian masses. J Comput Assist Tomogr 34:173-176
62. Medeiros LR, Freitas LB, Rosa DD et al (2011) Accuracy of magnetic resonance imaging in ovarian tumor: a systematic quantitative review. Am J Obstet Gynecol 204:67.e1-10
63. Buy JN, Ghossain MA, Sciot C et al (1991) Epithelial tumors of the ovary: CT findings and correlation with US. Radiology 178:811-818
64. Lapela M, Leskinen-Kallio S, Varpula M et al (1995) Metabolic imaging of ovarian tumors with carbon-11-methionine: a PET study. J Nucl Med 36:2196-2200
65. Grab D, Flock F, Stöhr I et al (2000) Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 77:454-459
66. Rieber A, Nüssle K, Stöhr I et al (2001) Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. AJR Am J Roentgenol 177:123-129
67. Ju W, Kim SC (2007) Discrepancy between magnetic resonance and 18F-fluorodeoxyglucose positron emission tomography imaging in a case of borderline ovarian tumor. Int J Gynecol Cancer 17:1031-1033
68. Yamamoto Y, Oguri H, Yamada R et al (2008) Preoperative evaluation of pelvic masses with combined 18F-fluorodeoxyglucose positron emission tomography and computed tomography. Int J Gynaecol Obstet 102:124-127
69. Jung DC, Choi HJ, Ju W et al (2008) Discordant MRI/FDG-PET imaging for the diagnosis of borderline ovarian tumors. Int J Gynecol Cancer 18:637-641
70. Risum S, Høgdall C, Loft A et al (2007) The diagnostic value of PET/CT for primary ovarian cancer-a prospective study. Gynecol Oncol 105:145-149
71. Nam EJ, Yun MJ, Oh YT et al (2010) Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. Gynecol Oncol 116:389-394
72. Poncelet C, Fauvet R, Yazbeck C et al (2010) Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: multivariate analysis of a French multicentre study. Eur J Surg Oncol 36:1066-1072
73. Van Calster B, Timmerman D, Bourne T et al (2007) Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. J Natl Cancer Inst 99:1706-1714
74. Van Holsbeke C, Van Calster B, Valentin L et al (2007) External validation of mathematical models to distinguish between benign and malignant adnexal tumors: a multicenter study by the International Ovarian Tumor Analysis Group. Clin Cancer Res 13:4440-4447
75. Jacobs I, Oram D, Fairbanks J et al (1990) A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. BJOG 97:922-929
76. Outwater EK, Huang AB, Dunton CJ et al (1997) Papillary projections in ovarian neoplasms: appearance on MRI. J Magn Reson Imaging 7:689-695